Clinical Trial Update: Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenvatinib plus toripalimab for platinum-resistant recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Recurrent Ovarian Carcinoma | Phase 2 | Status: UNKNOWN